Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers.

Biomed Res Int

Department of Basic Medical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA.

Published: September 2018

Eph receptors constitute the largest family of receptor tyrosine kinases, which are activated by ephrin ligands that either are anchored to the membrane or contain a transmembrane domain. These molecules play important roles in the development of multicellular organisms, and the physiological functions of these receptor-ligand pairs have been extensively documented in axon guidance, neuronal development, vascular patterning, and inflammation during tissue injury. The recognition that aberrant regulation and expression of these molecules lead to alterations in proliferative, migratory, and invasive potential of a variety of human cancers has made them potential targets for cancer therapeutics. We present here the involvement of Eph receptors and ephrin ligands in lung carcinoma, breast carcinoma, prostate carcinoma, colorectal carcinoma, glioblastoma, and medulloblastoma. The aberrations in their abundances are described in the context of multiple signaling pathways, and differential expression is suggested as the mechanism underlying tumorigenesis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851329PMC
http://dx.doi.org/10.1155/2018/7390104DOI Listing

Publication Analysis

Top Keywords

eph receptors
12
ephrin ligands
12
differential expression
8
receptors ephrin
8
human cancers
8
expression patterns
4
patterns eph
4
ligands human
4
cancers eph
4
receptors constitute
4

Similar Publications

Background: EphA2, a receptor-type tyrosine kinase, is overexpressed in several cancers, including colorectal cancer (CRC), and can be detected as soluble EphA2 in serum. This study aimed to investigate the relationship between soluble EphA2 and CRC.

Methods: Serum samples were collected from 65 patients with CRC and 19 healthy individuals.

View Article and Find Full Text PDF

Background: Paediatric sarcomas, including rhabdomyosarcoma, Ewing sarcoma and osteosarcoma, represent a group of malignancies that significantly contribute to cancer-related morbidity and mortality in children and young adults. These cancers share common challenges, including high rates of metastasis, recurrence or treatment resistance, leading to a 5-year survival rate of approximately 20% for patients with advanced disease stages. Despite the critical need, therapeutic advancements have been limited over the past three decades.

View Article and Find Full Text PDF

Inhibition of EphA2 by syndecan-4 in wounded skin regulates clustering of fibroblasts.

J Mol Cell Biol

December 2024

School of Biochemistry, University of Bristol, University Walk, Bristol BS8 1TD, United Kingdom.

Upon injury, fibroblasts in the surrounding tissue become activated, migrating into the wound in a controlled manner. Once they arrive, they contract the wound and remodel the stroma. While certain cell surface receptors promote fibroblast migration, others cause repulsion between fibroblasts upon contact, seemingly opposing their clustering within the wound bed.

View Article and Find Full Text PDF

EFNA4-enhanced deubiquitination of SLC7A11 inhibits ferroptosis in hepatocellular carcinoma.

Apoptosis

December 2024

Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, Guangzhou, 510315, China.

Article Synopsis
  • EFNA4 influences liver cancer (HCC) through two mechanisms: one that binds to Eph receptors and another that operates independently of them.
  • Despite a lack of Eph receptors, EFNA4 still promotes HCC cell growth and spread as well as inhibiting ferroptosis, a type of cell death.
  • The study reveals that EFNA4 interacts with the protein SLC7A11 to prevent its degradation, enhancing HCC progression and suggesting EFNA4 as a potential marker and target for HCC treatment.
View Article and Find Full Text PDF

Constrained β-Hairpins Targeting the EphA4 Ligand Binding Domain.

J Med Chem

December 2024

Division of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Avenue, Riverside, California 92521, United States.

The activity of the receptor tyrosine kinase EphA4 has been implicated in several pathologies including oncology (gastric and pancreatic cancers) and neurodegenerative diseases (amyotrophic lateral sclerosis and Alzheimer's disease). However, advances in validating EphA4 as a possible drug target have been limited by the lack of suitable pharmacological inhibitors. Recently, we reported on the design of potent EphA4 agonistic agents targeting its ligand binding domain (LBD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!